Trial of Anifrolumab in Active Systemic Lupus ErythematosusEric F. Morand, Raj Tummala, Yoshiya Tanaka et al.|New England Journal of Medicine|2019Cited by 1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 updateAntonis Fanouriakis, Dimitrios T. Boumpas, Myrto Kostopoulou et al.|Annals of the Rheumatic Diseases|2023Cited by 913
Treat-to-target in systemic lupus erythematosus: recommendations from an international task forceRonald van Vollenhoven, Matthias Schneider, Marta Mosca et al.|Annals of the Rheumatic Diseases|2014Cited by 726
A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease LociYing Liu, A. Bowcock, Cynthia Helms et al.|PLoS Genetics|2008Cited by 664
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialRichard Furie, Raj Tummala, Eric F. Morand et al.|The Lancet Rheumatology|2019Cited by 478